Search
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance...
Apr 9
Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program
Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest
Jun 26, 2024
Wave Life Sciences demonstrates high throughput oligonucleotide synthesis and talks RNA editing
Paul Bolno shows us how Wave discovers and develops its own oligonucleotides as Wave prepares to enter the clinic with RNA editing.
Aug 4, 2023
.png){kind=logo}
